Showing 1331-1340 of 2908 results for "".
- Vazegepant Relieves Pain And Most Bothersome Symptoms in Phase 2/3 Trialhttps://practicalneurology.com/news/vazegepant-relieves-pain-and-most-bothersome-symptoms-in-phase-23-trial/2469112/In a pivotal phase 2/3 clinical trial (NCT03872453), vazegepant (Biohaven Pharmaceutical, New Haven, CT). Participants in the trial (n=1,673) were randomly assigned to receive 5 mg, 10 mg, or 20 m
- Cenobamate Reduces Seizure Frequency Significantly in Phase 2 Trialhttps://practicalneurology.com/news/cenobamate-reduces-seizure-frequency-significantly-in-phase-3-trial/2469075/In the phase 2 trial (NCT01866111) treatment with cenobamate (SK Life Science, Paramus, NJ) resulted in statistically significant greater reductions in focal seizure frequency compared with baseline. Those treated with cenobamate 100 m
- Vamorolone Has Efficacy for Treating Duchenne Muscular Dystrophy Without Affecting Growthhttps://practicalneurology.com/news/vamorolone-has-efficacy-for-treating-duchenne-muscular-dystrophy-without-affecting-growth/2470013/In the VISION-DMD trial (NCT02760277), children with Duchenne muscular dystrophy (DMD) treated with vamorolone (ReveraGen BioPharma, Rockville, MD), had improved motor function with no negative effects on linear growth or biomarkers of
- Sargramostim Improves Motor Symptoms of Parkinson Disease in Small Phase 1 Trialhttps://practicalneurology.com/news/sargramostim-improves-motor-symptoms-of-parkinson-disease-in-small-phase-1-trial/2469597/An investigator-initiated clinical trial (NCT03790670) evaluated the use of sargramostim (Leukine; Partner Therapeutics, Lexington, MA). Improvements in MDS-UPDRS Part 3 scores, which measure motor sympto
- Validation of an Algorithmic EEG-Based Diagnostic Tool for Concussionhttps://practicalneurology.com/news/validation-of-an-algorithmic-eeg-based-diagnostic-tool-for-concussion/2469505/A study validating an EEG-based algorithmic concussion assessment tool (Concussion Index; Brainscope, Bethesda, MD) has been published in JAMA Open Network for evaluating severity of concussion
- Cannabidiol Reduces Seizures in People With Tuberous Sclerosis Complex-Related Seizures in Clinical Trialshttps://practicalneurology.com/news/cannabidiol-reduces-seizures-in-people-with-tuberous-sclerosis-complex-related-seizures-in-clinical-trials/2469097/Findings from a clinical trial (NCT02544763) presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD showed that people with tuberous sclerosis complex (TSC), a genetic condition associated with t
- Positive Phase 2 Results for Evobrutinib Treatment of MS and Initiation of Phase 3 Trialshttps://practicalneurology.com/news/positive-phase-2-results-for-evobrutinib-treatment-of-ms-and-initiation-of-phase-3-trials/2469014/At the European Committee on Research and Treatment in Multiple Sclerosis (ECTRIMS) Congress in Stockholm, Sweden September 11-13, 2019, data from a phase 2 trial (NCT02975349) of evobrutinib (EMD Serono, Rockland, MD) for treatment of
- Eye Tracking Technology Detects Traumatic Brain Injury With Sensitivity and Specificityhttps://practicalneurology.com/news/eye-tracking-technology-detects-traumatic-brain-injury-with-sensitivity-and-specificity/2469003/Research findings published in Concussion show that measurement of horizontal saccades with eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) has a 77% sensitivity and 78% specificity for i
- Study Evaluates Botox as Essential Tremor Treatmenthttps://practicalneurology.com/news/study-evaluates-botox-as-essential-tremor-treatment/2483937/Treatment with Botox (onabotulinumtoxinA; AbbVie, North Chicago, IL) was associated with significant improvements in functional outcomes in people with upper limb essential tremor (ET) compared with placebo in study results presented at the 2025 International Congress of Parkinson’s Disease and M
- Accelerated FDA Approval Granted to First Treatment Targeting H3 K27M-Mutant Diffuse Midline Gliomahttps://practicalneurology.com/news/fda-grants-accelerated-approval-to-first-treatment-targeting-h3-k27m-mutant-diffuse-midline-glioma/2476100/The Food and Drug Administration (FDA) granted accelerated approval to Modeyso (dordaviprone; Jazz Pharmaceuticals, Dublin, Ireland) for the treatment of adults and children aged ≥1 year with diffuse midline glioma harboring the H3 K27M mutation with disease progression following prior therapy. M